These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 8978799)

  • 1. [Etoposide (VP-16) in gynecologic malignancy].
    Kanazawa K; Moromizato H
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
    Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
    Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
    Surwit EA; Childers JM
    J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gestational trophoblastic disease.
    Hammond CB; Olt GJ
    Curr Ther Endocrinol Metab; 1994; 5():567-70. PubMed ID: 7704794
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI
    Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
    Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
    Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methotrexate in gynecologic oncology].
    Isonishi S; Terashima Y
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1896-900. PubMed ID: 8978793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of gestational trophoblastic disease.
    Omura GA
    J Clin Oncol; 2000 May; 18(10):2187. PubMed ID: 10811687
    [No Abstract]   [Full Text] [Related]  

  • 11. Poor-prognosis gestational trophoblastic disease: an update.
    Surwit EA; Alberts DS; Christian CD; Graham VE
    Obstet Gynecol; 1984 Jul; 64(1):21-6. PubMed ID: 6204257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placental site trophoblastic tumor: an overview.
    Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; Cantú MG
    J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-resistant gestational trophoblastic neoplasia treated successfully with cisplatin, etoposide, and bleomycin.
    Willemse PH; Aalders JG; Bouma J; Sleijfer DT
    Obstet Gynecol; 1988 Mar; 71(3 Pt 2):438-40. PubMed ID: 2450325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities.
    Matsui H; Iitsuka Y; Seki K; Sekiya S
    Gynecol Obstet Invest; 1998; 46(1):5-8. PubMed ID: 9692333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
    Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
    Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of high-risk gestational trophoblastic disease.
    Surwit EA
    J Reprod Med; 1987 Sep; 32(9):657-62. PubMed ID: 2822919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of high-risk gestational trophoblastic disease.
    Lurain JR
    J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
    Dobson LS; Lorigan PC; Coleman RE; Hancock BW
    Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.
    Soto-Wright V; Goldstein DP; Bernstein MR; Berkowitz RS
    Gynecol Oncol; 1997 Jan; 64(1):156-9. PubMed ID: 8995566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
    Cyriac S; Rajendranath R; Sridevi V; Sagar TG
    J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.